The Neuroscience Center

Medicine & Life Sciences

1. Migraine Disorders 100%
2. Multiple Sclerosis 84%
3. Headache 60%
4. Brain 48%
5. Denmark 42%
6. Alzheimer Disease 39%
7. Stroke 39%
8. Dementia 39%
9. Spinal Cord Injuries 38%
10. Therapeutics 36%
11. Traumatic Brain Injury 34%
12. Sleep 33%
13. Cerebrovascular Circulation 33%
14. Systematic Reviews 31%
15. Placebos 30%
16. Muscles 30%
17. Pain 29%
18. Cerebrospinal Fluid 27%
19. Population 25%
20. Randomized Controlled Trials 25%
21. Cohort Studies 25%
22. Biomarkers 24%
23. Cognitive Dysfunction 24%
24. Tension-Type Headache 24%
25. Magnetic Resonance Imaging 23%
26. Calcitonin Gene-Related Peptide 23%
27. Epilepsy 23%
28. Cluster Headache 22%
29. Healthy Volunteers 22%
30. Positron-Emission Tomography 21%
31. Exercise 21%
32. Brain Injuries 19%
33. Electroencephalography 19%
34. Intracranial Pressure 19%
35. Receptor, Serotonin, 5-HT2A 18%
36. Mutation 18%
37. Headache Disorders 18%
38. Genes 18%
39. Secondary Headache Disorders 17%
40. Narcolepsy 17%
41. Depression 17%
42. Subarachnoid Hemorrhage 17%
43. Mortality 16%
44. Serotonin 16%
45. Cognition 16%
46. White Matter 16%
47. Migraine with Aura 16%
48. Meta-Analysis 15%
49. Spinal Cord 15%
50. Rehabilitation 15%
51. Pharmaceutical Preparations 15%
52. Guidelines 14%
53. Relapsing-Remitting Multiple Sclerosis 14%
54. Registries 14%
55. Phenotype 14%
56. Wounds and Injuries 14%
57. Child 13%
58. Confidence Intervals 13%
59. Memory 13%
60. Neuroimaging 13%
61. Datasets 13%
62. Migraine without Aura 13%
63. Glycogen Storage Disease Type V 13%
64. Frontotemporal Dementia 13%
65. Quality of Life 13%
66. Intensive Care Units 13%
67. Safety 12%
68. REM Sleep Behavior Disorder 12%
69. Observational Studies 12%
70. Incidence 12%
71. Pseudotumor Cerebri 12%
72. Prospective Studies 12%
73. erenumab 11%
74. Parkinson Disease 11%
75. Seizures 11%
76. Single-Photon Emission-Computed Tomography 11%
77. Meningioma 11%
78. Health 11%
79. Elderly 11%
80. Optic Neuritis 10%
81. Multicenter Studies 10%
82. Sumatriptan 10%
83. Global Burden of Disease 10%
84. Oxygen 10%
85. Natalizumab 10%
86. Schizophrenia 10%
87. Huntington Disease 10%
88. Neoplasms 10%
89. Pharmacology 10%
90. Opioid Analgesics 9%
91. Genome-Wide Association Study 9%
92. Pituitary Adenylate Cyclase-Activating Polypeptide 9%
93. Recurrence 9%
94. Neurons 9%
95. Homeostasis 9%
96. Comorbidity 9%
97. Cross-Over Studies 9%
98. Hydrocephalus 9%
99. Glucose 9%
100. Bipolar Disorder 9%